FDA panel unanimously votes for GW Pharma's cannabis-derived epilepsy drug

(Reuters) - GW Pharmaceuticals Plc's cannabis-based drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.